"Treatment"

Bladder cancer is one of the common diseases nowadays. The incidence of cancer is still very high and many people are affected by cancer, so some bladder cancer patients want to know if the disease is hereditary

Pfizer's new treatment, Elranatamab, has received Breakthrough Therapy designation from the FDA for the treatment of patients with relapsed or refractory multiple myeloma. Data from the trial showed a patient efficacy rate of 61.0% and that once the therapy is effective, efficacy is maintained for more than six months in over 90% of patients!

If you are suffering from itchy hair and hair loss, it is important to understand the causes of itchy hair and hair loss so that you can get to the root of the problem. For example, some people only have mild hair loss, which can be relieved after certain adjustments, while others have both itchy symptoms and hair loss symptoms that are more pronounced, so it is also important to pay attention to the right treatment

The US FDA approved a new treatment for non-small cell lung cancer - Tremelimumab + Durvalumab + platinum-based chemotherapy. The triple combination therapy significantly improves efficacy and patient survival and has a good safety profile.

Recently, the European Commission has approved cemiplimab-rwlc (Libtayo), manufactured by US-based Regeneron, as a monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer whose disease has progressed during or after platinum-containing chemotherapy. The results of the trial showed that this therapy significantly improved patient survival and had a good safety profile.

The FDA granted Fast Track designation to a new drug, IK-175, in combination with nabumab for the treatment of advanced uroepithelial carcinoma, after preliminary trial data showed encouraging and durable anti-tumor activity with a favorable safety profile.

Stomach cancer can cause abnormal symptoms in the digestive system, even vomiting blood and black stools, so it should be treated promptly after having stomach cancer

Research suggests that gender-related differences in lung cancer survival are largely determined by known prognostic factors, suggesting an opportunity to explore gender differences in treatment preference, choice and accessibility.

A recent study led by the University of Texas Southwestern Medical Center on prostate cancer shows that by stopping the "transformation" of cancer cells in prostate cancer, new treatments are expected to overcome drug resistance.

The European Union has approved the marketing of the new treatment Opdualag for the treatment of melanoma patients. New data demonstrates that the treatment resulted in the complete disappearance of tumours in 16.3% of patients, a significant reduction in tumours in 26.8% and stable disease without further progression in 18.2% of patients, giving an efficiency rate of 61.3%.